Indiana 2025 Regular Session

Indiana House Bill HB1604

Introduced
1/21/25  
Refer
1/21/25  
Report Pass
2/11/25  
Engrossed
2/18/25  
Refer
3/3/25  
Report Pass
3/20/25  
Enrolled
3/26/25  
Passed
5/6/25  
Chaptered
5/6/25  

Caption

Cost sharing; out-of-pocket expense credit.

Impact

The proposed legislation is expected to have a significant impact on the structure of health insurance policies in Indiana. It mandates that health plans credit costs paid directly to providers for covered services toward deductibles and out-of-pocket maximums, which could lead to reduced financial barriers for patients seeking necessary care. By ensuring compliance with federal regulations, the bill aims to enhance the predictability of out-of-pocket costs related to crucial medications, thereby improving overall health outcomes for covered individuals.

Summary

House Bill 1604 aims to modify the Indiana Code by establishing rules regarding cost sharing for health care services and prescription drugs. The bill focuses on ensuring that cost sharing for particular prescription drugs, specifically those that are life-saving or intended to manage chronic pain and do not have an approved generic, adheres to limits set in the federal Affordable Care Act. This measure seeks to provide financial relief and greater accessibility to critical medications for residents of Indiana.

Sentiment

Stakeholder sentiment around HB 1604 appears to be largely positive, particularly among healthcare advocates and patient support groups who argue that the bill represents a step forward in protecting patients from exorbitant costs associated with essential drug therapies. However, there are concerns from some insurance companies about the administrative burden and potential impacts on premium pricing. Overall, the sentiment reflects a desire for a balance between accessible care and the economic realities of healthcare funding.

Contention

Notably, there have been discussions regarding the oversight and operational roles of pharmacy benefit managers in relation to the new provisions introduced by HB 1604. Concerns have been raised about how pharmacy benefit managers will adapt to these requirements and whether they will be able to maintain compliance without compromising the quality or availability of healthcare services. The bill also opens up discussions about the cost implications for insurers and how this might affect overall healthcare costs in the state.

Companion Bills

No companion bills found.

Similar Bills

AZ HB2291

Opioids; containers; labeling; requirements; repeal

CA AB577

Health care coverage: antisteering.

RI H8318

Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.

RI S2889

Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.

HI SB2751

Relating To Workers' Compensation.

HI HB2225

Relating To Health.

RI H5866

Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.

RI S0795

Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.